These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8811373)

  • 21. Dicloxacillin and flucloxacillin twice daily with probenecid in staphylococcal infections. A clinical and pharmakokinetic evaluation.
    Hedström SA; Kahlmeter G
    Scand J Infect Dis; 1980; 12(3):221-5. PubMed ID: 7433922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The activity of isoxazolyl penicillins in experimental staphylococcal infection.
    Renneberg J; Forsgren A
    J Infect Dis; 1989 Jun; 159(6):1128-32. PubMed ID: 2723456
    [No Abstract]   [Full Text] [Related]  

  • 23. Dicloxacillin pharmacokinetics in dogs after intravenous, intramuscular and oral administration.
    Dimitrova DJ; Pashov DA; Dimitrov DS
    J Vet Pharmacol Ther; 1998 Oct; 21(5):414-7. PubMed ID: 9811444
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacokinetics of amoxicillin and flucloxacillin following the simultaneous intravenous administration of 4 g and 1 g, respectively.
    Adam D; Koeppe P; Heilmann HD
    Infection; 1983; 11(3):150-4. PubMed ID: 6885174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma protein binding of dicloxacillin: effects of age and diseases.
    Pacifici GM; Viani A; Taddeucci-Brunelli G; Rizzo G; Carrai M
    Int J Clin Pharmacol Ther Toxicol; 1987 Nov; 25(11):622-6. PubMed ID: 3429065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxicities of flucloxacillin and dicloxacillin--is there really a difference?
    Gosbell IB; Turnidge JD; Tapsall JW; Benn RA
    Med J Aust; 2000 Nov; 173(9):500-1. PubMed ID: 11149309
    [No Abstract]   [Full Text] [Related]  

  • 27. Bioavailability and half-life of two preparations of flucloxacillin.
    Paton DM; Mander P; Avery RJ
    N Z Med J; 1982 Nov; 95(719):766-8. PubMed ID: 6959033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and distribution of flucloxacillin in pacemaker patients.
    Anderson P; Bluhm G; Ehrnebo M; Herngren L; Jacobson B
    Eur J Clin Pharmacol; 1985; 27(6):713-9. PubMed ID: 3987776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparative study of the efficacy, safety and tolerance of azithromycin, dicloxacillin and flucloxacillin in the treatment of children with acute skin and skin-structure infections.
    Rodriguez-Solares A; Pérez-Gutiérrez F; Prosperi J; Milgram E; Martin A
    J Antimicrob Chemother; 1993 Jun; 31 Suppl E():103-9. PubMed ID: 8396081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral absorption of flucloxacillin in infants and young children.
    Bergdahl S; Eriksson M; Finkel Y; Lännergren K
    Acta Pharmacol Toxicol (Copenh); 1986 Apr; 58(4):255-8. PubMed ID: 3716820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postmarketing surveillance: strengths and limitations. The flucloxacillin-dicloxacillin story.
    Boyd IW
    Med J Aust; 1999 Aug; 171(4):219. PubMed ID: 10494242
    [No Abstract]   [Full Text] [Related]  

  • 32. Population pharmacokinetic modelling of total and unbound flucloxacillin in non-critically ill patients to devise a rational continuous dosing regimen.
    Wilkes S; van Berlo I; Ten Oever J; Jansman F; Ter Heine R
    Int J Antimicrob Agents; 2019 Mar; 53(3):310-317. PubMed ID: 30472288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flucloxacillin in bone.
    Unsworth PF; Heatley FW; Phillips I
    J Clin Pathol; 1978 Aug; 31(8):705-11. PubMed ID: 690233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver damage from flucloxacillin, cloxacillin and dicloxacillin.
    Olsson R; Wiholm BE; Sand C; Zettergren L; Hultcrantz R; Myrhed M
    J Hepatol; 1992 May; 15(1-2):154-61. PubMed ID: 1506634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation.
    Yu W; Ji J; Xiao T; Ying C; Fang J; Shen P; Xiao Y
    Drug Des Devel Ther; 2017; 11():1951-1956. PubMed ID: 28721014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The metabolic disposition of flucloxacillin in patients with impaired kidney function.
    Thijssen HH; Wolters J
    Eur J Clin Pharmacol; 1982; 22(5):429-34. PubMed ID: 7117355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Endothelial damage caused by the semisynthetic penicillins cloxacillin dicloxacillin and flucloxacillin].
    Sinapius D; Bründel KH
    Vasa; 1975; 4(1):54-8. PubMed ID: 1189592
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of mezlocillin on the pharmacokinetics of oxacillin and dicloxacillin.
    Kampf D
    J Antimicrob Chemother; 1983 May; 11 Suppl C():25-32. PubMed ID: 6619039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between penicillinase production and the in-vitro activity of methicillin, oxacillin, cloxacillin, dicloxacillin, flucloxacillin, and cephalothin against strains of Staphylococcus aureus of different phage patterns and penicillinase activity.
    Frimodt-Møller N; Rosdahl VT; Sørensen G; Hartzen SH; Bentzon MW
    J Antimicrob Chemother; 1986 Jul; 18(1):27-33. PubMed ID: 3489704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of dicloxacillin in serum and aortic wall during aneurysmal surgery.
    Almgren B; Cars O; Eriksson I; Erlendsdóttir H
    Acta Chir Scand; 1986 Jan; 152():19-21. PubMed ID: 3953214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.